QSYMIA
Drug
VIVUS, Inc.
Total Payments
$13.0M
Transactions
14,741
Doctors
5,458
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $143,972 | 2,228 | 1,445 |
| 2023 | $4.1M | 2,244 | 1,316 |
| 2022 | $1.8M | 2,487 | 1,499 |
| 2021 | $1.3M | 109 | 4 |
| 2020 | $3.7M | 1,205 | 571 |
| 2019 | $889,934 | 2,348 | 1,176 |
| 2018 | $538,170 | 1,775 | 908 |
| 2017 | $616,059 | 2,345 | 1,365 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.1M | 688 | 70.0% |
| Royalty or License | $3.0M | 29 | 23.4% |
| Consulting Fee | $464,846 | 92 | 3.6% |
| Food and Beverage | $261,151 | 13,808 | 2.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $89,055 | 50 | 0.7% |
| Travel and Lodging | $43,998 | 71 | 0.3% |
| Education | $24.78 | 3 | 0.0% |
Payments by Type
Research
$9.1M
688 transactions
General
$3.9M
14,053 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject | VIVUS LLC | $4.4M | 0 |
| A Phase IV Safety and Efficacy of VI-0521 in Obese Adolescents | VIVUS, Inc. | $3.4M | 0 |
| A Phase IV Safety and Efficacy of VI-0521 in Obese Adolescents | VIVUS LLC | $792,163 | 0 |
| IIT - Anti Obesity Pharmacotherapy vs Patients Using a Wearable Activity Tracker | VIVUS LLC | $379,938 | 0 |
| IIT - Anti Obesity Pharmacotherapy vs Patients Using a Wearable Activity Tracker | VIVUS, Inc. | $155,393 | 0 |
Top Doctors Receiving Payments for QSYMIA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Winston-Salem, NC | $9.1M | 689 |
| Thomas Najarian | — | Incline Village, NV | $3.0M | 29 |
| , MD | Cardiovascular Disease | Chestnut Hill, MA | $263,659 | 51 |
| , M.D., J.D | Family Medicine | Schaumburg, IL | $68,542 | 33 |
| , MD | Public Health & General Preventive Medicine | Washington, DC | $55,471 | 16 |
| , M.D., PH.D | Internal Medicine | Rochester, MN | $33,144 | 13 |
| , M.D | Pediatrics | Brooklyn, NY | $26,796 | 11 |
| , MD | Endocrinology, Diabetes & Metabolism | Sterling, VA | $17,924 | 28 |
| , MD | Surgery | New York, NY | $17,899 | 21 |
| , M.D | Endocrinology, Diabetes & Metabolism | Jacksonville, FL | $12,226 | 60 |
| , M.D | Family Medicine | Daytona Beach, FL | $10,933 | 24 |
| , PA | Medical | Glen Ellyn, IL | $10,735 | 16 |
| , MD | Cardiovascular Disease | San Francisco, CA | $9,420 | 5 |
| , M.D | Endocrinology, Diabetes & Metabolism | Rockville, MD | $6,856 | 4 |
| , MD | Endocrinology, Diabetes & Metabolism | Loxahatchee, FL | $6,342 | 10 |
| , M.D | Endocrinology, Diabetes & Metabolism | Plano, TX | $5,573 | 11 |
| , MD | Neurology | Emerald Hills, CA | $5,300 | 2 |
| , MD | Adolescent Medicine | San Antonio, TX | $5,278 | 8 |
| , MD | Pulmonary Disease | Portola Valley, CA | $4,584 | 4 |
| , M.D | Endocrinology, Diabetes & Metabolism | West Palm Beach, FL | $3,846 | 11 |
| , M.D | Internal Medicine | San Diego, CA | $3,409 | 3 |
| , MD | Student in an Organized Health Care Education/Training Program | Denton, TX | $3,273 | 29 |
| , M.D | Pediatrics | Valhalla, NY | $3,105 | 4 |
| Cynthia Rudert | — | Atlanta, GA | $2,927 | 22 |
| , MD | Internal Medicine | Weston, MA | $2,863 | 2 |
Ad
Manufacturing Companies
- VIVUS LLC $7.3M
- VIVUS, Inc. $5.8M
Product Information
- Type Drug
- Total Payments $13.0M
- Total Doctors 5,458
- Transactions 14,741
About QSYMIA
QSYMIA is a drug associated with $13.0M in payments to 5,458 healthcare providers, recorded across 14,741 transactions in the CMS Open Payments database. The primary manufacturer is VIVUS, Inc..
Payment data is available from 2017 to 2024. In 2024, $143,972 was paid across 2,228 transactions to 1,445 doctors.
The most common payment nature for QSYMIA is "Unspecified" ($9.1M, 70.0% of total).
QSYMIA is associated with 5 research studies, including "A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject" ($4.4M).